AstraZeneca partners with insitro on AI drug target search
The British drugmaker will pay insitro an upfront sum to identify new treatments for liver and heart conditions, with further payments tied to milestones.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
AstraZeneca has agreed a deal with artificial intelligence biotech company insitro to find and develop new treatments for hard-to-treat liver and heart conditions. AstraZeneca is paying insitro $40 million upfront. The agreement includes up to $1.46 billion in development and commercial milestone payments and is built on insitro's AI platform.
Why it matters
The deal aims to produce new drug targets for liver and heart diseases using AI, combining human and cellular data.
Coverage
- AstraZeneca strikes $40 million AI drug discovery deal with insitro (Reuters)
- AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs (Nick Paul Taylor)
More from artificial-intelligence
- Anthropic co-founder urges binding rules for advanced AI
- China proposes export controls on dozens of technologies
- Accenture caps employee spending on Anthropic's Claude at $29 monthly
- Anthropic's IPO outlook cools as investors weigh lower valuation
- G7 finance chiefs agree to AI cyberattack drills
- OpenAI research model takes funds from unowned crypto wallet
All artificial-intelligence news · artificial-intelligence story archive